The Use of Nitrosative Stress Molecules as Potential Diagnostic Biomarkers in Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) of still unclear etiology. In recent years, the search for biomarkers facilitating its diagnosis, prognosis, therapy response, and other parameters has gained increasing attention. In this regard, in a previous meta...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-01, Vol.25 (2), p.787
Main Authors: Räuber, Saskia, Förster, Moritz, Schüller, Julia, Willison, Alice, Golombeck, Kristin S, Schroeter, Christina B, Oeztuerk, Menekse, Jansen, Robin, Huntemann, Niklas, Nelke, Christopher, Korsen, Melanie, Fischer, Katinka, Kerkhoff, Ruth, Leven, Yana, Kirschner, Patricia, Kölsche, Tristan, Nikolov, Petyo, Mehsin, Mohammed, Marae, Gelenar, Kokott, Alma, Pul, Duygu, Schulten, Julius, Vogel, Niklas, Ingwersen, Jens, Ruck, Tobias, Pawlitzki, Marc, Meuth, Sven G, Melzer, Nico, Kremer, David
Format: Article
Language:English
Subjects:
Autoimmune Diseases
Biological markers
Biological products industry
Biomarkers
Care and treatment
Central Nervous System
Comparative analysis
Cytokines
Development and progression
Diagnosis
Disease
Humans
Leukocytes
Medically Unexplained Symptoms
Multiple sclerosis
Multiple Sclerosis - diagnosis
Multiple Sclerosis, Relapsing-Remitting
Nitrogen dioxide
Nitrogen oxide
Nitrosative Stress
Ofatumumab
Oxidation
Pharmaceutical industry
Physiology
Tumor necrosis factor-TNF
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) of still unclear etiology. In recent years, the search for biomarkers facilitating its diagnosis, prognosis, therapy response, and other parameters has gained increasing attention. In this regard, in a previous meta-analysis comprising 22 studies, we found that MS is associated with higher nitrite/nitrate (NOx) levels in the cerebrospinal fluid (CSF) compared to patients with non-inflammatory other neurological diseases (NIOND). However, many of the included studies did not distinguish between the different clinical subtypes of MS, included pre-treated patients, and inclusion criteria varied. As a follow-up to our meta-analysis, we therefore aimed to analyze the serum and CSF NOx levels in clinically well-defined cohorts of treatment-naïve MS patients compared to patients with somatic symptom disorder. To this end, we analyzed the serum and CSF levels of NOx in 117 patients (71 relapsing-remitting (RR) MS, 16 primary progressive (PP) MS, and 30 somatic symptom disorder). We found that RRMS and PPMS patients had higher serum NOx levels compared to somatic symptom disorder patients. This difference remained significant in the subgroup of MRZ-negative RRMS patients. In conclusion, the measurement of NOx in the serum might indeed be a valuable tool in supporting MS diagnosis.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms25020787